Acadia shareholders elect directors, approve 2024 equity plan at annual meeting

ACADIA PHARMACEUTICALS INC

Julian C. Baker, Stephen R. Biggar, and Daniel B. Soland elected as Class II directors.
2024 Equity Incentive Plan approved with 131.3M votes for, 9.4M against.
Say-on-pay advisory vote passed with 132.99M for, 7.64M against.
Ernst & Young ratified as independent auditor for FY2024 with 150.0M for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.